Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling

Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy. The development of new CRPC treatment strategies is strongly impeded by the scarcity of representative, scalable and transferable preclinical models of advanced, androgen receptor (AR)-driven CRPC. Here, we prese...

Descripción completa

Detalles Bibliográficos

Autores principales:	Annelies Van Hemelryk, Ingrid Tomljanovic, Corrina M. A. de Ridder, Debra C. Stuurman, Wilma J. Teubel, Sigrun Erkens-Schulze, Esther I. Verhoef, Sebastiaan Remmers, Amrish J. Mahes, Geert J. L. H. van Leenders, Martin E. van Royen, Harmen J. G. van de Werken, Magda Grudniewska, Guido W. Jenster, Wytske M. van Weerden
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-11-01
Colección:	Cells
Materias:	castration-resistant prostate cancer patient-derived xenografts organoids androgen receptor drug testing
Acceso en línea:	https://www.mdpi.com/2073-4409/11/22/3632
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!